Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials - Concepedia

Concepedia

Publication | Open Access

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

DOI Full Paper Access

46

Citations

13

References

2018

Year

Jason D. Lickliter, Tino F. Schwarz, Casey Johnson, Laurence Chu, Joseph B. Domachowske, Pierre Van Damme, Kanchanamala Withanage, Laurence Fissette, Marie‐Pierre David, Koen Maleux,

The Journal of Infectious Diseases

Abstract

All formulations of RSV-PreF boosted preexisting immune responses in 18-45-year old women with comparable immunogenicity. The RSV-PreF safety profile was similar to that of Tdap vaccine.

References

	Year	Citations

Page 1